SPIE Membership Get updates from SPIE Newsroom
  • Newsroom Home
  • Astronomy
  • Biomedical Optics & Medical Imaging
  • Defense & Security
  • Electronic Imaging & Signal Processing
  • Illumination & Displays
  • Lasers & Sources
  • Micro/Nano Lithography
  • Nanotechnology
  • Optical Design & Engineering
  • Optoelectronics & Communications
  • Remote Sensing
  • Sensing & Measurement
  • Solar & Alternative Energy
  • Sign up for Newsroom E-Alerts
  • Information for:
    Advertisers
SPIE Photonics West 2018 | Call for Papers

SPIE Journals OPEN ACCESS

SPIE PRESS

SPIE PRESS




Print PageEmail PageView PDF

Biomedical Optics & Medical Imaging

An optical method for early detection of Alzheimer's disease

A method using targeted fluorescent probes in cerebrospinal fluid could detect Alzheimer's disease several years earlier than current exams.
4 March 2015, SPIE Newsroom. DOI: 10.1117/2.1201502.005825

Alzheimer's Disease (AD) is currently diagnosed using neuropsychological tests. These differentiate between mild cognitive impairment (MCI), AD, and other dementia types. However, the pathogenic process of AD begins several years before the clinical onset of the disease, and it induces measurable changes in the brain, cerebrospinal fluid (CSF), and the blood. There is a worldwide effort to develop treatments to prevent, cure, or delay the progression of AD. If we had a diagnostic tool for early detection of the disease based on its pathological expressions, we could significantly advance the development of such treatments, and increase their effectiveness.

Purchase SPIE Field Guide to MicroscopyA promising approach for early detection of AD is based on measuring the concentration ratio of amyloid-beta and tau proteins in the CSF. Several studies using this approach showed that it is possible to predict the development of MCI to AD several years before clinical diagnosis of the disease.1, 2 However, to measure concentrations of CSF biomarkers, it is necessary to collect CSF from patients during a lumbar puncture procedure. This involves many risks and complications and may not be suitable as an annual test. To overcome these drawbacks, we proposed3 an optical method that replaces the lumbar puncture process and enables estimation of the CSF biomarkers concentration ratio.

Our proposed method, described in Figure 1, has several stages. First, we inject fluorescent probes4–7 that bind specifically to the CSF biomarkers into the blood. We then insert a miniature needle with an optical fiber into the lumbar area. It passes several tissue layers until it reaches the epidural fat, without penetrating the dura mater (a membrane around the brain). Laser radiation reaches the CSF through the optical fiber in the needle and excites the fluorescent biomarkers. We measure the resultant emission and use the ratio of fluorescence intensities to estimate the biomarkers' concentration ratio and the risk of developing AD. The method does not require a priori information about the tissue's optical properties.


Figure 1. The proposed setup. Stage 1: Injection of two fluorescent probes. Stage 2 : Measuring the fluorescence intensity of the two probes using a needle near the cerebrospinal fluid. Stage 3: Calculating the concentration ratio of amyloid-beta (Aβ) and tau proteins based on the fluorescence intensity ratio and estimating the risk of developing Alzheimer's Disease. NIR: Near-IR. PMT: Photomultiplier (detector).

To ensure the feasibility of our technique, we developed a theoretical model of photon propagation in the lumbar area to simulate the relationship between the measured fluorescence emission and the biomarkers' concentration ratio. We then used Monte-Carlo simulations to show that sufficient energy reaches the detector. We tested the accuracy of the method experimentally in vitro using multi-layered tissue phantoms. We prepared these with different scattering and absorption coefficients, thicknesses, and fluorescence concentrations to simulate variations in human anatomy and AD stages, as well as the needle location. We further tested the method's accuracy ex vivo using chicken breast tissue.

For in vitro experiments, we performed a total of 120 measurements on three-layered phantoms simulating the bone, CSF, and epidural fat layers. The bone layer was made of delrin (a synthetic polymer), and the epidural fat layer was made of polyester resin with titanium dioxide. We modeled the CSF using a cuvette with fluorescent samples. We measured 15 fluorescent samples, varied in their concentration ratio, with eight different polyester slabs varying in thickness and scattering coefficient. Figure 2 presents the estimated versus true concentration ratio. Each data point is the average estimated value of eight measurements, using the different polyester slabs, with its 90% confidence interval. The mean absolute error of the 15 estimated values presented in Figure 2 is 4.4% with a standard deviation of 2.5%.


Figure 2. The estimated concentration ratio as a function of the true concentration ratio, for the multi-layered tissue phantom experiments. The solid line represents the true ratio values. The star symbols represent the average estimated ratios with their 90% confidence interval. The dotted lines represent the true ratio values with 5% errors and the dash-dotted lines represent the true ratio values with 10% errors.

To better simulate the variations in the human spectra, we tested the method using four sets of ex vivo samples of chicken tissue. Figure 3 presents the estimated versus true concentration ratio. Each data point is the average estimated value of four measurements (performed on different excitation locations on the non-uniform tissue slab) with its 90% confidence interval. The mean absolute error of the estimated values presented in Figure 3 is 10.9% with a standard deviation of 7.8%.


Figure 3. The estimated concentration ratio as a function of the true concentration ratio for the chicken tissue experiments. The solid line represents the true ratio values. The star symbols represent the average estimated ratios with their 90% confidence interval. The dash-dotted lines represent the true ratio values with 15% errors.

We tested our method for optical detection of AD using fluorescent probes in the CSF with Monte Carlo simulations in in-vitro and ex-vivo experiments. These validated the possibility of accurately estimating the ratio of amyloid-beta and tau proteins in the CSF. The method does not require any a priori knowledge regarding the tissue's anatomical and optical properties and is performed without the need to penetrate the dura mater and collect CSF samples. Our next step is to demonstrate the method's accuracy in vivo and to verify its suitability as an annual screening test that will assist in the early diagnosis of AD.


Osnat Harbater, Israel Gannot
Tel Aviv University
Tel-Aviv, Israel

Osnat Harbater is a PhD candidate in the Biomedical Engineering Department. Her research interests include photon propagation models in tissue, novel optical methods for diagnosing Alzheimer's disease, monitoring cerebral hemodynamics, and optical imaging modalities.

Israel Gannot is a professor of biophotonics at Tel Aviv University and at Johns Hopkins University. His field of research is multi-modal diagnostic and treatment methods based on nanoparticles, early detection of diseases based on fluorescence imaging, lasers tissue interactions, and optical fibers and sensing for medical applications.


References:
1. P. Buchhave, L. Minthon, H. Zetterberg, A. K. Wallin, K. Blennow, O. Hansson, Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer Dementia, Arch. Gen. Psych. 69, p. 98, 2012.
2. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, S.-K. Herukka, W. M. van der Flier, M. A. Blankenstein, M. Ewers, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, J. Am. Med. Assoc. 302, p. 385-393, 2009.
3. O. Harbater, I. Gannot, Fluorescent probes concentration estimation in vitro and ex vivo as a model for early detection of Alzheimer's disease, J. Biomed. Opt. 19, p. 127007, 2014. doi:10.1117/1.JBO.19.12.127007
4. S. B. Raymond, J. Skoch, I. D. Hills, E. E. Nesterov, T. M. Swager, B. J. Bacskai, Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology, Euro. J. Nucl. Med. Mol. Imag. 35, p. 93-98, 2008.
5. M. Hintersteiner, A. Enz, P. Frey, A.-L. Jaton, W. Kinzy, R. Kneuer, U. Neumann, M. Rudin, M. Staufenbiel, M. Stoeckli, In vivo detection of amyloid-βdeposits by near-infrared imaging using an oxazine-derivative probe, Nat. Biotechnol. 23, p. 577-583, 2005.
6. C. Ran, X. Xu, S. B. Raymond, B. J. Ferrara, K. Neal, B. J. Bacskai, Z. Medarova, A. Moore, Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits, J. Am. Chem. Soc. 131, p. 15257-15261, 2009.
7. N. Okamura, M. Mori, S. Furumoto, T. Yoshikawa, R. Harada, S. Ito, Y. Fujikawa, H. Arai, K. Yanai, Y. Kudo, In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265, J. Alzh. Dis. 23, p. 37-48, 2011.